Your prediction
Investigator Resources Ltd Stock
Investigator Resources Ltd dominated the market today, gaining €0.001 (4.650%).
Pros and Cons of Investigator Resources Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Investigator Resources Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Investigator Resources Ltd | 4.650% | -2.273% | -23.214% | 104.762% | -75.287% | -2.273% | -40.278% |
| Strategic Energy Resources | 4.440% | -16.149% | -23.729% | 13400.000% | 13400.000% | 1127.273% | 170.000% |
| Black Ridge Mining Ltd | -4.000% | -7.407% | -3.846% | 733.333% | 1150.000% | 108.333% | 92.308% |
| Elementos Ltd | 1.600% | -10.096% | -15.000% | 199.200% | 11.976% | 107.778% | -6.500% |
News
Palvella Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Palvella Therapeutics, Inc.? Here are five stocks we like better.
- Palvella remains on track to submit its NDA for QTORIN rapamycin in microcystic lymphatic
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Key Points
- Interested in Turn Therapeutics Inc.? Here are five stocks we like better.
- Turn Therapeutics refined the stage two design of its GX-03 phase II eczema trial after an interim